Syneron Bio said it has closed a $150 million Series B to support its macrocyclic peptide development platform, following a multibillion-dollar biobucks deal with AstraZeneca and a nearly $100 million raise earlier. The financing underscores continued investor appetite for peptide engineering platforms with diversified drug discovery capabilities. Company plans are expected to focus on expanding peptide lead discovery and progression, aiming to convert platform chemistry into clinical candidates. In the current biotech funding environment, scale-up capital often signals urgency around pipeline timelines and platform productivity. Syneron’s next milestones will likely include preclinical-to-clinical transitions, manufacturing readiness, and partnership updates that show the AstraZeneca collaboration is producing actionable assets.